Bio-Path Holdings Reports Third Quarter 2023 Financial Results
November 15, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
November 08, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
October 24, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023 16:01 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
August 15, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
August 08, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
August 03, 2023 08:22 ET
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi...
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
August 01, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
Interim Data Analysis Demonstrates Significant Clinical Improvement and Tolerable Safety Profile in High-Risk Patients Company Provides Clinical Development Plan Update with Pathways to...
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
July 17, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports First Quarter 2023 Financial Results
May 12, 2023 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...